COVID-19 outcomes in people with cystic fibrosis.
COVID-19 outcomes in people with cystic fibrosis.
复制标题
DOI：
10.1097/mcp.0000000000000823
复制
发表时间：
2021-11-01
影响因子：
3.3
通讯作者：
Goss C
中科院分区：
文献类型：
--
作者：
Burgel PR;Goss C
由严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）引起的COVID-19全球大流行已产生巨大影响，目前仍在全球范围内持续。囊性纤维化（CF）已被确定为一个可能的危险因素，不良的结果。世界各地多个国家CF登记处收集的数据表明，CF（PwCF）患者受SARS-CoV-2影响的可能性并不比普通人群高。SARS-CoV-2的病程在相对年轻的PwCF中通常是轻度的。在低肺功能患者和免疫抑制患者（即实体器官移植）中描述了严重结局。还观察到该流行病对社区保健设施社区的间接影响，包括社区保健设施护理组织方面的困难，导致妇女福利和保健设施的远程保健急剧增加。大流行病使正在进行的临床试验复杂化，进一步影响了临床研究。疫苗接种对所有PwCF都很重要，特别优先考虑为移植受体制定适当的疫苗接种计划。COVID-19对CF人群的长期影响仍然未知。COVID-19疫情对PwCF及提供专业CF护理及临床研究的医护专业人员造成重大影响。
The COVID-19 global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a dramatic impact that is still ongoing around the world. Cystic fibrosis (CF) has been identified as a possible risk factor of poor outcome. Data collected by multiple National CF registries around the world have indicated that persons with CF (PwCF) are not more likely to be affected by SARS-CoV-2 than the general population. The course of SARS-CoV-2 is usually mild in PwCF who are relatively young. Severe outcomes have been described in patients with low lung function and in those with immune suppression (i.e. solid organ transplantation). Indirect impact of the pandemic on the CF community have also been observed, including difficulties in the organization of CF care, leading to a dramatic increase in telehealth for PwCF. The pandemic has further affected clinical research by complicating ongoing clinical trials. Vaccination appears important to all PwCF, with special priority on developing adequate vaccination scheme for transplant recipients. Long-term effects of COVID-19 on the CF population remains unknown. The COVID-19 pandemic has caused significant impacts on PwCF and on healthcare professionals who provide specialized CF care and clinical research.